Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
• • A—HUMAN NECESSITIES
  • A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
  • A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
  • A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
  • A24B15/10—Chemical features of tobacco products or tobacco substitutes
  • A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
  • A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/007—Pulmonary tract; Aromatherapy
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
  • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/10—Dispersions; Emulsions
  • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M15/00—Inhalators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M2202/00—Special media to be introduced, removed or treated
  • A61M2202/04—Liquids
  • A61M2202/0468—Liquids non-physiological
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M2207/00—Methods of manufacture, assembly or production
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
  • A61M2210/00—Anatomical parts of the body
  • A61M2210/10—Trunk
  • A61M2210/1025—Respiratory system

Definitions

• the invention generally relates to apparatus, systems, formulations, and methods pertaining to liquids that are aerosolized and inhaled by persons using electronic devices, whether intended for personal or recreational use, or for the administration of medicines.
• Inhalation delivery systems now play an increasing role in the targeted delivery of active ingredients to the human pulmonary system. This is true both for medical purposes, such as the targeted delivery of anti-cancer medications to the lungs, as well as for recreational/personal purposes, such as vaping, in which a liquid that includes the active ingredient is vaporized using heating so that the active ingredient can be inhaled into the human body.
• inhalation delivery systems using heating have increased in prominence, concerns about their short and long term safety have come into focus. This is particularly true for vaping where there exist ongoing concerns about the possible presence of harmful and potentially harmful constituents (HPHCs) in the inhaled vapor.
• HPHCs harmful and potentially harmful constituents
• inhalation delivery systems are often unable to provide the desired effect to a user. This may be attributable to the pre-vaporized liquid becoming unstable over time or the active ingredient itself not being properly sized or dispersed for deposition in the alveolar lung.
• the invention includes many aspects and features. Moreover, while many aspects and features relate to, and are described in, the context of THC/CBD delivery systems, the invention is not limited to use only in pulmonary delivery of THC/CBD, as will become apparent from the following summaries and detailed descriptions of aspects, features, and one or more embodiments of the invention.
• a liquid-filled cartridge for use with an electronic device for delivery of a substance into a body through respiration comprises: a liquid container; and (b) a liquid contained within the container for aerosolizing and inhaling by a person using the electronic device, the liquid comprising a plurality of nanoparticles in a nanoemulsion, each nanoparticle comprising an encapsulation of the substance to be delivered into the body through respiration.
• the liquid is an oil-in-water nanoemulsion.
• each nanoparticle is a micelle .
• each nanoparticle is a liposome.
• the substance is encapsulated by a polymer.
• the substance is encapsulated by a surfactant.
• the surfactant preferably comprises high purity polyoxyethylene sorbitan monooleate.
• the encapsulated substance comprises tetrahydrocannabinol.
• the encapsulated substance comprises cannabidiol.
• the encapsulated substance comprises tetrahydrocannabinol and cannabidiol.
• the encapsulated substance comprises a pharmaceutical compound.
• the encapsulated substance comprises nicotine.
• the nanoparticles are suspended within an aqueous solution.
• the aqueous solution preferably comprises a saline; the aqueous solution preferably comprises sodium chloride; and, the nanoparticles preferably are suspended within an aqueous solution of 0.9% sodium chloride.
• a pH of the liquid is between about 5.5 and about 8.
• a pH of the liquid is between about 6.5.
• a molecular ratio of the encapsulated substance to an encapsulating agent of the nanoparticle between about 0.1 : 1 to about 10: 1.
• a polydispersity index measurement of the liquid is less than 0.3.
• the cartridge is a single-use, disposable cartridge.
• the cartridge is refillable.
• a method of manufacturing cartridges for use with an electronic device for delivery of a substance into a body through respiration comprises fdling a liquid container of the cartridge with a liquid for aerosolizing and inhaling by a person using the electronic device, the liquid comprising a plurality of nanoparticles in a nanoemulsion, each nanoparticle comprising an encapsulation of the substance to be delivered into the body through respiration.
• the method further comprises a preliminary step of producing the nanoemulsion by processing the substance to be delivered together with the encapsulating agent using a microfluidizing machine.
• the method further comprises operating the microfluidizing machine such that a temperature of the processing does not exceed 65°C while producing the nanoemulsion.
• the method further comprises the step of adjusting pH of the nanoemulsion so as to be between about 5.5 and 8.
• the method further comprises the step of chemically bonding the substance to be encapsulated with another molecule prior to processing the substance with the encapsulating agent using the microfluidizing machine.
• the polydispersity index measurement of the nanoemulsion after processing using the microfluidizing machine preferably is less than 0.3.
• a method of manufacturing a liquid for aerosolizing and inhaling by a person using an electronic device for the delivery of a substance to the body of the person through respiration comprising producing a liquid comprising a plurality of nanoparticles in a nanoemulsion by processing the substance together with an encapsulating agent using a microfluidizing machine such that the plurality of nanoparticles of the liquid comprises the encapsulated substance.
• the method further comprises operating the microfluidizing machine such that a temperature of the processing does not exceed 65°C while producing the liquid.
• the method further comprises adjusting pH of the nanoemulsion so as to be between about 5.5 and 8.
• the method further comprises the step of chemically bonding the substance to be encapsulated with another molecule prior to processing the substance with the encapsulating agent using the microfluidizing machine.
• a polydispersity index measurement of the nanoemulsion after processing using the microfluidizing machine is less than 0.3.
• the liquid formulation includes an aqueous solution, one or more encapsulating agents, and an active ingredient or “value added molecule(s)”.
• the active ingredient is encapsulated by one or more encapsulating agents to form a nanoparticle.
• the nanocarrier comprises a liposome.
• the nanocarrier comprises a micelle.
• the nanoparticles have an average diameter of less than 1 ,000 nanometers.
• the one or more encapsulating agents comprise a polymer.
• the one or more encapsulating agents comprise a surfactant.
• the surfactant comprises a high purity polyoxyethylene sorbitan monooleate, such as “SUPER REFINED Polysorbate 80”.
• the aqueous solution comprises a saline solution.
• the saline solution comprises a 0.9% saline solution.
• the active ingredient comprises tetrahydrocannabinol.
• the active ingredient comprises cannabidiol.
• the active ingredient comprises tetrahydrocannabinol and cannabidiol.
• the active ingredient comprises nicotine.
• the active ingredient comprises a pharmaceutical compound.
• a ratio of the one or more encapsulating agents to the active ingredient is between about 0.1:1 to about 10:1.
• a pH measurement of the liquid formulation is between about 5.5 and about 8. In another feature of this aspect, a pH measurement of the liquid formulation is about 6.5. [ 043 ] In another feature of this aspect, a polydispersity index measurement of the liquid formulation is less than 0.3. [ 044 ] In another feature of this aspect, the active ingredient is chemically bonded to another molecule.
• Another aspect of the invention relates to a method of preparing a liquid formulation for aerosolization.
• the method comprises the steps of mixing nanoparticles that include an active ingredient in a solution to form a liquid mixture and processing the liquid mixture with a microfluidizer.
• a temperature of the liquid mixture does not exceed 65°C during the processing step.
• the method further comprises the step of adjusting the pH of the liquid mixture.
• the method further comprises the step of chemically bonding the active ingredient with another molecule.
• nanoparticles of the microfluidized liquid mixture have an average diameter less than 1,000 nanometers.
• a polydispersity index measurement of the microfluidized liquid mixture is less than 0.3.
• the solution comprises an aqueous solution.
• the aqueous solution comprises a 0.9% saline solution.
• the nanoparticles comprise encapsulated nanoparticles.
• the active ingredient is contained within the encapsulated nanoparticles.
• the nanocarrier comprises a liposome.
• the nanocarrier comprises a micelle.
• the active ingredient comprises tetrahydrocannabinol.
• the active ingredient comprises cannabidiol.
• the active ingredient comprises tetrahydrocannabinol and cannabidiol.
• the active ingredient comprises nicotine.
• the active ingredient comprises a pharmaceutical compound.
• FIG. l is a schematic diagram of an active ingredient pulmonary delivery nanoparticle in the form of a micelle in accordance with one or more aspects of the invention.
• FIG. 2 is a schematic diagram of an active ingredient pulmonary delivery nanoparticle in the form of a liposome carrying an active ingredient within a bilayer in accordance with one or more aspects of the invention.
• FIG. 3 is a schematic diagram of an active ingredient pulmonary delivery nanoparticle in the form of a liposome carrying an active ingredient in a hydrophilic core in accordance with one or more aspects of the invention.
• any sequence(s) and/or temporal order of steps of various processes or methods that are described herein are illustrative and not restrictive. Accordingly, it should be understood that, although steps of various processes or methods may be shown and described as being in a sequence or temporal order, the steps of any such processes or methods are not limited to being carried out in any particular sequence or order, absent an indication otherwise. Indeed, the steps in such processes or methods generally may be carried out in various different sequences and orders while still falling within the scope of the invention. Accordingly, it is intended that the scope of patent protection afforded the invention be defined by the issued claim(s) rather than the description set forth herein.
• a picnic basket having an apple is the same as “a picnic basket comprising an apple” and “a picnic basket including an apple”, each of which identically describes “a picnic basket having at least one apple” as well as “a picnic basket having apples”; the picnic basket further may contain one or more other items beside an apple.
• a picnic basket having a single apple describes “a picnic basket having only one apple”; the picnic basket further may contain one or more other items beside an apple.
• a picnic basket consisting of an apple has only a single item contained therein, i.e., one apple; the picnic basket contains no other item.
• picnic basket having cheese or crackers describes “a picnic basket having cheese without crackers”, “a picnic basket having crackers without cheese”, and “a picnic basket having both cheese and crackers”; the picnic basket further may contain one or more other items beside cheese and crackers.
• picnic basket having cheese and crackers describes “a picnic basket having cheese, wherein the picnic basket further has crackers”, as well as describes “a picnic basket having crackers, wherein the picnic basket further has cheese”; the picnic basket further may contain one or more other items beside cheese and crackers.
• Liquid means a substance that flows freely but is of constant volume, generally having a consistency like that of water (lower viscosity) or oil (higher viscosity). Liquid is generic to and encompasses a solution, a suspension, and an emulsion.
• Solution means a homogeneous mixture of two or more components.
• the dissolving agent is the solvent.
• the substance that is dissolved is the solute.
• the components of a solution are atoms, ions, or molecules, and the components are usually a nanometer or less in any dimension.
• An example of a solution is sugar mixed with water.
• “Suspension” means a mixture of components that can be evenly distributed by mechanical methods such as shaking or stirring, but that will eventually settle out over an extended period of time.
• the components in a suspension are generally larger than those in solutions.
• An example of a suspension is oil mixed with water.
• Colloidal dispersion means a heterogenous liquid mixture in which a component is dispersed in another component and does not tend to settle out over an extended period of time.
• the dispersed components generally is larger than components of a solution and smaller than components of a suspension.
• “Aerosol” means a colloidal dispersion of a solid or liquid in a gas.
• Embodision means a colloidal dispersion of a liquid in a liquid.
• An example of an emulsion is milk.
• Nanoemulsion means an emulsion in which the dispersed component comprises nanoparticles.
• Nanoparticle means a molecule has — or aggregate of molecules have — having no dimension greater than about a micrometer (1,000 nanometers). In accordance with preferred embodiments of aspects and features of the invention, nanoparticles preferably have a dimension of between about 50 and about 200 nanometers.
• “Micelle” means a vesicle having a layer of molecules that encapsulate and transport a substance to cells of a body.
• the encapsulating molecules in a micelle may be surfactants or polymers, for example.
• a typical micelle in an aqueous solution forms an aggregate with the hydrophilic “head” regions in contact with the surrounding solvent, creating a hydrophobic tail region in the interior of the aggregate.
• “Liposome” means a vesicle having at least one bilayer of molecules that encapsulates and transports a substance to cells of a body.
• Microfluidizing machine means an apparatus that uses microreactor technology to make nanoemulsions through the interaction of liquid streams in defined microchannels. Such technology is described, for example, in U.S. patent application publications 2012/0236680 and 2019/0299171. Microfluidizing machines principally utilize high shear forces and impact to emulsify a liquid-liquid system, dispersing one immiscible liquid into another within an interaction chamber. A “Y” chamber preferably is used and may be single-slotted or multi-slotted.
• microreactor technology comprises a large pump that forces a formulation through a very small orifice (i.e., microchannel) at pressures ranging from as low as 3.4 MPa (500 psi) to as high as 275 MPa(40,000 psi).
• Preferred microfluidizing machines correspond to the processors manufactured, sold, or distributed by Mircofluidics of Newton or Westwood, Massachusetts, under the registered trademark MICROFLUIDIZER, and any and all other apparatus that have the same or equivalent structure for performing the same or equivalent function with the same or equivalent result.
• An active ingredient delivery system for inhalation in accordance with the invention is contemplated to be capable of accommodating and delivering a range of different types of active ingredients to the body through the pulmonary system.
• Active ingredients capable of delivery using one or more delivery systems described herein include, but are not limited to, pharmaceutical compounds, tetrahydrocannabinol (THC), cannabidiol (CBD), and nicotine.
• THC tetrahydrocannabinol
• CBD cannabidiol
• nicotine nicotine.
• THC tetrahydrocannabinol
• CBD cannabidiol
• the following description of embodiments sets forth one or more active ingredient delivery systems largely within the context of delivering THC and/or CBD, but it should be understood that active ingredient delivery systems described herein are also usable for delivery of nicotine, pharmaceuticals, micronutrients, and other types of active ingredients by inhalation and are not limited to delivery of THC/CBD.
• THC and CBD are two of several different cannabinoids found in plants of the Cannabis genus. Using extraction techniques, THC and CBD can be isolated from the plant matrix for medicinal and/or recreational use. THC and CBD interact with different receptors in the human brain and, thus, cause a different treatment or effect in the user.
• THC and CBD may be referenced together as “THC/CBD.” It should be understood that, as used herein, “THC/CBD” refers to a cannabinoid-based active ingredient that includes both THC and CBD, THC without CBD, or CBD without THC.
• THC and CBD are hydrophobic molecules that do not readily mix with aqueous solutions like water.
• THC/CBD molecules are encapsulated into nanoparticles comprising oil droplets of the THC/CBD active ingredient surrounded by one or more encapsulation agents, such as surfactants or emulsifiers, which shield the oil droplets from the surrounding aqueous environment.
• the shielded oil droplets can then mix into aqueous solutions.
• One example of such a mixture is a nanoemulsion, where the oil phase includes the hydrophobic THC/CBD molecules shielded by one or more surfactants from the surrounding aqueous phase.
• FIG. l is a schematic diagram of an active ingredient pulmonary delivery nanoparticle in the form of a micelle 10 in accordance with one or more aspects of the invention.
• the hydrophobic droplet 12 comprised of oil containing THC/CBD molecules is surrounded by a monolayer 14 of one or more encapsulation agents, which forms an aggregate.
• the monolayer 14 is a lipid-based monolayer. Molecules forming the monolayer 14 include hydrophilic heads 16 that are in contact with the surrounding aqueous solution 40 and hydrophobic tails 18 that extend toward the micelle center.
• FIG. 2 is a schematic diagram of an active ingredient pulmonary delivery nanoparticle in the form of a liposome 20 carrying an active ingredient 60 within a bilayer in accordance with one or more aspects of the invention.
• the oil component resides in a hydrophobic area 22 of the liposome 20 between a bilayer of one or more encapsulation agents.
• the bilayer is a lipid-based bilayer.
• Molecules that form the outer layer 24 of the bilayer include hydrophilic heads 28 that are in contact with the surrounding aqueous solution 50 and hydrophobic tails 30 that extend into the hydrophobic area 22 between the layers 22,24.
• Lipid molecules that form the inner layer 26 of the bilayer include hydrophilic heads 32 that are in contact with the aqueous solution 52 at the center of the liposome 20 and hydrophobic tails 34 that extend into the hydrophobic area 22 of the bilayer.
• the hydrophilic heads 28,32 form the boundaries of the bilayer that facilitate isolation of the hydrophobic area, which includes the hydrophobic active ingredient 60.
• the liposome 20 can be mixed into the surrounding aqueous solution 50.
• the liposome 20 is largely spherical in shape, although non-spherical shapes are also possible.
• the liposome 20 and the surrounding aqueous solution 50 are contained within a cartridge 100.
• Liquid mixtures that include active ingredient delivery nanoparticles in accordance with FIGS. 1 or 2 include an active ingredient, an encapsulation agent, and an aqueous solution.
• active ingredient includes THC/CBD molecules, although a wide range of other active ingredients are contemplated to be deliverable to the human pulmonary system in accordance with the invention, including, but not limited to, pharmaceutical compounds, micronutrients, and nicotine.
• Encapsulation agents to encapsulate hydrophobic active ingredient molecules are compounds with a hydrophobic region and a hydrophilic region. It is contemplated that encapsulation agents include, but are not limited to, lipids, polymers, and surfactants.
• Encapsulation agents can be used singly or in combination with each other.
• the aqueous solution is a medium that can be selected and formulated to achieve an osmotic balance with respect to human physiology.
• the aqueous solution is a 0.9% saline solution, which is understood to provide a preferred osmotic balance with human physiology of the lungs.
• a 0.9% saline solution as the aqueous medium facilitates a safer user experience, particularly when the liquid mixture is aerosolized.
• polymers include, but are not limited to, poly(lactic-co-glycolic) acid (PLGA), polylactic acid (PLA), polyglycolic acid (PGA), polycaprolactone (PCL), and polyhydroxybutyrate (PHB).
• PLGA poly(lactic-co-glycolic) acid
• PLA polylactic acid
• PGA polyglycolic acid
• PCL polycaprolactone
• PHB polyhydroxybutyrate
• surfactants include, but are not limited to: high purity polyoxyethylene sorbitan monooleate (also known by its trade name, SUPER REFINED® Polysorbate 80); polyoxyethylene sorbitan monooleate; (also known by its trade name, TWEEN® Polysorbate 80); polyoxyethylene sorbitan monostearate (also known by its trade name TWEEN® Polysorbate 60); polyoxyethylene sorbitan monopalmitate (also known by its trade name TWEEN® Polysorbate 40); polyoxyethylene sorbitan monolaurate (also known by its trade name TWEEN® Polysorbate 20); lecithin; dipalmitoylphosphatidylcholine (DPPC); l,2-distearoyl-s «-glycero- 3-phosphocholine (DSPC); sorbitan monostearate (also known by its trade name SPAN 60); and sorbitan monopalmitate (also known
• a ratio of surfactant combinations is determined by hydrophilic-lipophilic balance (HLB) values inherent to each surfactant.
• HLB hydrophilic-lipophilic balance
• the combination of surfactants yields a weighted average HLB value that can be used to match the target application in order to enhance or optimize mixing of nanoparticles containing the active ingredient into the aqueous solution. For example, an HLB value measuring from approximately 8 to approximately 16 is satisfactory for oil-in-water emulsions.
• the encapsulating agent includes a high purity or high-grade surfactant, which is understood to enhance the shelf-life of the resulting mixture as well as to improve the efficacy and safety of the resulting mixture.
• a high purity surfactant that can be used in the formulation is high purity polyoxyethylene sorbitan monooleate, which is also known by its trade name, SUPER REFINED® Polysorbate 80.
• SUPER REFINED® Polysorbate 80 is manufactured and sold by Croda International Pic of the United Kingdom.
• a ratio of the surfactant relative to the active ingredient affects the size of the resulting nanoparticles (e.g., micelles and/or liposomes that contain the active ingredient).
• the surfactant-to-active-ingredient ratio can range from approximately 0.1 : 1 to approximately 10:1. Size of the resulting nanoparticles that contain the active ingredient affects a variety of characteristics of the final product, including pulmonary deposition of the active ingredient, absorption of the active ingredient, and the product shelf-life.
• a process for producing a liquid mixture that includes active- ingredient nanocarriers in accordance with FIGS. 1-3 is accomplished using a microfluidics approach.
• Microfluidics involves utilizing a network of channels having very small dimensions to process the liquid mixture in order to achieve homogeneous mixture with consistently-sized nanoparticles.
• a microfluidizer is utilized to achieve the desired nanoparticle dispersal and uniform mixture with consistently-sized nanoparticles.
• a temperature of the liquid mixture does not exceed a temperature threshold of 65 °C.
• processing the liquid mixture using a microfluidizer facilitates processing without the use of chemical solvents, which further reduces the risk of generating harmful HPHCs in the final liquid mixture.
• use of a microfluidics approach helps to maintain sterility in the materials used to produce the final liquid mixture, which also enhances consumer safety.
• the processed liquid includes nanoparticles of a uniformly small size and a low polydispersity index (PD I) value.
• PD I polydispersity index
• THC/CBD nanoparticles in the final liquid mixture have an average diameter less than 1,000 nanometers or, alternatively, have a dimension that is no larger than 1,000 nanometers. It is believed that nanoparticles of this scale provide enhanced pulmonary deposition of the active ingredient into the alveolar lung region, which facilitates increased pulmonary absorption. Furthermore, nanoparticles of this scale enhance the stability of the final liquid mixture, which increases its shelf-life.
• the final liquid mixture has a PDI value measuring less than 0.3.
• the PDI value provides a measurement of the broadness of size distribution.
• a low PDI value is indicative of a high level of particle size uniformity in a mixture.
• the PDI value is 0.3 or less, which is believed to indicate a liquid mixture with increased stability and enhanced shelf-life.
• a PDI measurement scale assigns a value of 0.0 to a population of particles where the particles have a perfectly uniform size and a value of 1.0 to a highly polydisperse population of particles with multiple size populations.
• the pH of the final liquid mixture can be adjusted to accommodate a specific objective.
• a pH value of the final liquid mixture that is greater than approximately 3 and less than approximately 10 can improve the inhalation experience for the user by reducing a cough reaction.
• the final liquid mixture includes many THC/CBD-encapsulated nanoparticles that are uniformly suspended in an aqueous solution for downstream aerosolization by an aerosolizing device for inhalation.
• aerosolizing devices may include, for example, vaporizers and nebulizers.
• the encapsulated molecules are chemically bonded to other molecules in a conjugated system. Establishing a conjugated system with chemical bonds between the active ingredient molecules and other molecules facilitates more efficient encapsulation of the active ingredients via the techniques described herein. In some contemplated embodiments, then THC/CBD molecules are chemically bonded with molecules of stearic acid and/or oleic acid. Establishing a conjugated system, as described herein, is understood to enhance or optimize encapsulation of THC/CBD molecules as well as other drugs or pharmaceutical compounds.
• formulations and methods as described herein can be applied to hydrophobic drugs or compounds other than THC/CBD. It is further contemplated that formulations and methods as described herein can be applied to hydrophilic drugs or compounds with modifications.
• One such modification includes encapsulating the hydrophilic drug or compound into a hydrophilic core of a liposomal nanoparticle.
• Another such modification includes conjugation of the hydrophilic drug or compound to a hydrophobic molecule (such as by chemical bonding) in order to achieve an overall hydrophobic compound capable of being encapsulated in the manner as set forth in FIGS. 1 and 2.
• FIG. 3 is a schematic diagram of an active ingredient pulmonary delivery nanoparticle in the form of a liposome 120 carrying a hydrophilic active ingredient 160 in a hydrophilic core 158 in accordance with one or more aspects of the invention.
• the hydrophobic component resides in a hydrophobic area 122 of the liposome 120 between a bilayer of one or more encapsulation agents.
• the bilayer is a lipid-based bilayer.
• Molecules that form the outer layer 124 of the bilayer include hydrophilic heads 128 that are in contact with the surrounding aqueous solution 150 and hydrophobic tails 130 that extend into the hydrophobic area 122 of the bilayer.
• Lipid molecules that form the inner layer 126 of the bilayer include hydrophilic heads 132 that are in contact with the aqueous solution 152 at the core 158 of the liposome 120 and hydrophobic tails 134 that extend into the hydrophobic area 122 of the bilayer.
• the hydrophilic heads 128,132 form the barriers of the bilayer that facilitate isolation of the hydrophobic area 122.
• the hydrophilic active ingredient 160 is contained within the hydrophilic core 158.
• the liposome 120 can be mixed into the surrounding aqueous solution 150. As indicated in FIG. 3, the liposome 120 is largely spherical in shape, although non-spherical shapes are also possible. Also , the liposome 120 and the surrounding aqueous solution 150 are contained within a cartridge 100. [098] In at least some embodiments, it is further contemplated that the aqueous solution of the product can be buffered to mitigate pH over time. In this respect, it is contemplated that a saline solution can be converted to a phosphate buffer saline solution. Buffering the solution with the addition of a buffering agent can enhance consistency of the product, increase the shelf-life, and enhance the consumer experience when the product is aerosolized during use.
• additives can be included in the aqueous solution of the product.
• Contemplated additives include, but are not limited to antioxidants (such as ascorbic acid, sodium ascorbate, or others) and preservatives (such as antimicrobials).
• antioxidants such as ascorbic acid, sodium ascorbate, or others
• preservatives such as antimicrobials.
• additives can provide a safer consumer experience when the product is aerosolized during use.
• additives can enhance the shelf-life of the product.
• Additives can also be used to enhance or complement the user experience.
• additives can be included to enhance or complement the smell/taste during inhalation of the aerosolized product.
• Additives to enhance or complement the smell/taste during inhalation include, but are not limited to, menthol and mint.
• additives can be included to enhance or complement the inhalation sensation during inhalation of the aerosolized product.
• An additive that enhances or complements the inhalation sensation might mimic a throat hit sensation commonly associated with nicotine inhalation or the sensation might trigger a feeling of smoothness for the consumer.
• a carrier or diluent solution is used in connection with the active ingredient to increase stability of the resulting product. Additionally, a carrier or diluent solution can enhance manufacturing process efficiency with respect to the ability to encapsulate the active ingredient when forming the nanoparticles.
• a carrier or diluent solution includes a medium-chain triglyceride (MCT) oil.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• General Chemical & Material Sciences (AREA)
• Dispersion Chemistry (AREA)
• Pulmonology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Engineering & Computer Science (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biophysics (AREA)
• Molecular Biology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=75620791

Family Applications (1)

Country Status (4)

Family Cites Families (13)

• 2020
  • 2020-10-20 EP EP20878561.8A patent/EP4044843A4/de active Pending
  • 2020-10-20 WO PCT/US2020/056541 patent/WO2021081010A1/en not_active Ceased
  • 2020-10-20 TW TW109136340A patent/TW202128132A/zh unknown
  • 2020-10-20 CA CA3155369A patent/CA3155369A1/en active Pending

Also Published As

Similar Documents

Legal Events